The Effect of Molecular Diagnostics on the Treatment of Glioma

doi:10.1007/s11912-017-0585-6

Review

. 2017 Apr;19(4):26.

doi: 10.1007/s11912-017-0585-6.

The Effect of Molecular Diagnostics on the Treatment of Glioma

Nancy Ann Oberheim Bush¹, Nicholas Butowski²

Affiliations

¹ Division of Neuro-Oncology, Department of Neurological Surgery, University of California, 400 Parnassus Ave, A808, San Francisco, CA, USA.
² Division of Neuro-Oncology, Department of Neurological Surgery, University of California, 400 Parnassus Ave, A808, San Francisco, CA, USA. Nicholas.Butowski@ucsf.edu.

PMID: 28303493
DOI: 10.1007/s11912-017-0585-6

Review

The Effect of Molecular Diagnostics on the Treatment of Glioma

Nancy Ann Oberheim Bush et al. Curr Oncol Rep. 2017 Apr.

. 2017 Apr;19(4):26.

doi: 10.1007/s11912-017-0585-6.

Authors

Nancy Ann Oberheim Bush¹, Nicholas Butowski²

Affiliations

¹ Division of Neuro-Oncology, Department of Neurological Surgery, University of California, 400 Parnassus Ave, A808, San Francisco, CA, USA.
² Division of Neuro-Oncology, Department of Neurological Surgery, University of California, 400 Parnassus Ave, A808, San Francisco, CA, USA. Nicholas.Butowski@ucsf.edu.

PMID: 28303493
DOI: 10.1007/s11912-017-0585-6

Abstract

Purpose of review: This review summarizes the use of molecular diagnostics in glioma and its effect on the development of novel therapeutics and management decisions.

Recent findings: Genomic and proteomic profiling of brain tumors has provided significant expansion of our understanding of oncogenesis, characterization, and prognostication of brain tumors. Molecular markers such as MGMT, EGFR, IDH, 1p19q, ATRX, TERT, FGFR-TACC, and BRAF are now being used to classify brain tumors as well as influence management decisions. Several of these markers are also being used as therapeutic targets. We review the use of several molecular diagnostics in gliomas and discuss their impact on drug development and clinical trial design. In the future, molecular characterization based on a specific genomic, proteomic as well as transcriptomes for bioformatics analysis will provide clinicians the ability to rationally select drugs with actionable targets for each patient.

Keywords: 1p/19q; EGFR; Glioblastoma; Glioma; IDH; MGMT.

PubMed Disclaimer

Cited by

The E3 ubiquitin ligase RBCK1: Implications in the tumor immune microenvironment and antiangiogenic therapy of glioma.
Guo J, Sun D, Zhang J, Guo J, Wu Z, Chen Y, Xu Y, Zhou D, Cui Y, Mo Q, Li Y, Zhao T, You Q. Guo J, et al. Comput Struct Biotechnol J. 2023 Oct 13;21:5212-5227. doi: 10.1016/j.csbj.2023.10.020. eCollection 2023. Comput Struct Biotechnol J. 2023. PMID: 37928949 Free PMC article.
A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human Glioma.
Koehler JW, Miller AD, Miller CR, Porter B, Aldape K, Beck J, Brat D, Cornax I, Corps K, Frank C, Giannini C, Horbinski C, Huse JT, O'Sullivan MG, Rissi DR, Mark Simpson R, Woolard K, Shih JH, Mazcko C, Gilbert MR, LeBlanc AK. Koehler JW, et al. J Neuropathol Exp Neurol. 2018 Nov 1;77(11):1039-1054. doi: 10.1093/jnen/nly085. J Neuropathol Exp Neurol. 2018. PMID: 30239918 Free PMC article.
Radiomics Features Predict CIC Mutation Status in Lower Grade Glioma.
Zhang L, Giuste F, Vizcarra JC, Li X, Gutman D. Zhang L, et al. Front Oncol. 2020 Jun 26;10:937. doi: 10.3389/fonc.2020.00937. eCollection 2020. Front Oncol. 2020. PMID: 32676453 Free PMC article.
Proteomic Advances in Glial Tumors through Mass Spectrometry Approaches.
Pirlog R, Susman S, Iuga CA, Florian SI. Pirlog R, et al. Medicina (Kaunas). 2019 Jul 27;55(8):412. doi: 10.3390/medicina55080412. Medicina (Kaunas). 2019. PMID: 31357616 Free PMC article. Review.
Molecular Markers of Therapy-Resistant Glioblastoma and Potential Strategy to Combat Resistance.
Nguyen HS, Shabani S, Awad AJ, Kaushal M, Doan N. Nguyen HS, et al. Int J Mol Sci. 2018 Jun 14;19(6):1765. doi: 10.3390/ijms19061765. Int J Mol Sci. 2018. PMID: 29899215 Free PMC article. Review.

See all "Cited by" articles

References

1. J Clin Oncol. 2011 Aug 1;29(22):3050-5 - PubMed
1. Science. 2013 May 3;340(6132):626-30 - PubMed
1. Neurology. 2007 May 22;68(21):1831-6 - PubMed
1. J Clin Oncol. 2013 Jan 20;31(3):337-43 - PubMed
1. J Clin Oncol. 2000 Feb;18(3):636-45 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

[1] J Clin Oncol. 2011 Aug 1;29(22):3050-5 - PubMed

[2] J Clin Oncol. 2011 Aug 1;29(22):3050-5 - PubMed

[3] Science. 2013 May 3;340(6132):626-30 - PubMed

[4] Science. 2013 May 3;340(6132):626-30 - PubMed

[5] Neurology. 2007 May 22;68(21):1831-6 - PubMed

[6] Neurology. 2007 May 22;68(21):1831-6 - PubMed

[7] J Clin Oncol. 2013 Jan 20;31(3):337-43 - PubMed

[8] J Clin Oncol. 2013 Jan 20;31(3):337-43 - PubMed

[9] J Clin Oncol. 2000 Feb;18(3):636-45 - PubMed

[10] J Clin Oncol. 2000 Feb;18(3):636-45 - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The Effect of Molecular Diagnostics on the Treatment of Glioma

Affiliations

The Effect of Molecular Diagnostics on the Treatment of Glioma

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Research Materials

Miscellaneous